CD4 and cancer: Despite these differences in their mechanisms of action, the results demonstrated that, in all 4 different cancer cell lines tested, combinations of CD4/6 inhibitors, e.g. ribociclib and palbociclib, and the 6 cytotoxic agents, given either concurrently or sequentially failed to consistently produce an additive or synergistic cytotoxic effect.